Deciphering the chemical language of host-microbiome communication
Visiting speaker
Marco Jost
Assistant Professor of Microbiology, Harvard Medical School
Past Talk
Hybrid talk
Wednesday
Jan 17, 2024
Watch video
2:00 pm
EST
Virtual
177 Huntington Ave.
11th floor
Devon House
58 St Katharine's Way
London E1W 1LP, UK
Online
Register here

Efforts to define the physiological impacts of the human microbiome have led to several intriguing findings. First, thousands of small molecules of microbial origin are present in human blood or stool at micro- to millimolar concentrations. Second, phenomenological studies in animals have implicated some of these molecules in immune system development, behavioral phenotypes, and many additional processes. Third, variations in abundances of these molecules in humans are associated with autoimmune and neurological disorders, among others. Subsequent mechanistic investigations have revealed new biology, such as microbiome-derived small molecules that induce genotoxicity or impact atherosclerosis by binding adrenergic receptors on platelets. Together, these findings imply that microbiome-derived small molecules form the language of a cross-kingdom chemical dialogue that plays an important role in human biology. The main goal of our research is to define this dialogue from its chemical underpinnings to its physiological consequences. In my presentation, I will discuss our overarching goals, and how we tackle these goals using a combination of systematic phenotypic screens and high-throughput genetics, using examples from our ongoing work to illustrate both.

About the speaker
About the speaker
Marco Jost is currently an Assistant Professor of Microbiology at Harvard Medical School. He holds a diploma in biochemistry from the University of Tübingen in Germany and a PhD in Biological Chemistry from MIT. For his PhD, he worked with Cathy Drennan to study the role of coenzyme B12 in photosensing and radical catalysis. He then conducted postdoctoral work with Jonathan Weissman and Carol Gross at UCSF, where he developed CRISPR screening methods, and used them to identify the molecular target of an anti-cancer drug and to probe glycolipid signaling at the host-microbiome interface. He started his lab in April 2021 and focuses on understanding how the human microbiome impacts human health.
Marco Jost is currently an Assistant Professor of Microbiology at Harvard Medical School. He holds a diploma in biochemistry from the University of Tübingen in Germany and a PhD in Biological Chemistry from MIT. For his PhD, he worked with Cathy Drennan to study the role of coenzyme B12 in photosensing and radical catalysis. He then conducted postdoctoral work with Jonathan Weissman and Carol Gross at UCSF, where he developed CRISPR screening methods, and used them to identify the molecular target of an anti-cancer drug and to probe glycolipid signaling at the host-microbiome interface. He started his lab in April 2021 and focuses on understanding how the human microbiome impacts human health.